VAJİNİTLER
KAYNAKLAR
1. Abdallah M, Augenbraun MH, McCormak W. Vulvovaginitis and Cervicitis. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases.
9th edition. Philadelphia, PA: Elsevier; 2020.
2. Marnach ML, Wygant JN, Casey PM. Evaluation and Management of Vaginitis. Mayo Clin Proc 2022; 97: 347-358.
3. Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215. Obstet Gynecol 2020; 135: e1-e17.
4. Kalia N, Singh J, Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. Ann Clin Microbiol Antimicrob 2020; 19: 5.
5. Powell AM, Nyirjesy P. Recurrent vulvovaginitis. Best Pract Res Clin Obstet Gynaecol 2014; 28: 967–976.
6. World Health Organization. Guidelines for the management of sexually transmitted infections. Geneva: WHO; 2003.
7. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. Atlanta: Centers for Disease Control and Prevention; 2010.
8. Sherrard J, Wilson J, Donders G, Mendling W, Jensen JS. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation
(WHO) guideline on the management of vaginal discharge. Int J STD AIDS 2018; 29: 1258–1272.
9. Saraf VS, Sheikh SA, Ahmad A, Gillevet PM, Bokhari H, Javed S. Vaginal microbiome: normalcy vs dysbiosis. Arch Microbiol 2021; 203: 3793-3802.
10. Saunders S, Bocking A, Challis J, Reid G. Efect of Lactobacillus challenge on gardnerella vaginalis bioflms. Colloids Surf B Biointerfaces 2007; 55: 138–142.
11. Oakley BB, Fiedler TL, Marrazzo JM, Fredricks DN. Diversity of human vaginal bacterial communities and associations with clinically defned bacterial vaginosis. Appl Environ Microbiol
2008; 74: 4898–4909.
12. van de Wijgert JHHM, Jespers V. The global health impact of vaginal dysbiosis. Res Microbiol 2017; 168: 859-864.
13. Smith SB, Ravel J. The vaginal microbiota, host defense and reproductive physiology. J Physiol 2017; 595: 451-463.
14. Lamont RF, Sobel JD, Akins RA, et al. The vaginal microbiome: new information about genital tract fora using molecular based techniques. BJOG 2011; 118: 533–549.
15. Mitchell C, Fredricks D, Agnew K, Hitti J. Hydrogen peroxideproducing lactobacilli are associated with lower levels of vaginal interleukin-1b, independent of bacterial vaginosis. Sex Transm
Dis 2015; 42: 358-363.
16. Paavonen J, Brunham RC. Bacterial vaginosis and desquamative inflammatory vaginitis. N Engl J Med 2018; 378: 2246-2254.
17. Singh RH, Zenilman JM, Brown KM, Madden T, Gaydos C, Ghanem KG. The role of the physical examination in diagnosing common causes of vaginitis: a prospective study. Sex Transm
Infect 2013; 89: 185–190.
18. Sherrard J, Wilson J, Donders G, Mendling W, Jensen JS. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation
(WHO) guideline on the management of vaginal discharge. Int J STD AIDS 2018; 29: 1258-1272.
19. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex
Transm Dis 2007; 34: 864-869.
20. Schwebke JR, Muzny CA, Josey WE. Role of Gardnerella vaginalis in the pathogenesis of Bacterial Vaginosis: A Conceptual Model. J Infect Dis 2014; 10: 338-343.
21. ACOG MicroRounds Series Units I-V Bacterial Vaginosis. www.acog.org/education-and-events/emodules/bacterial-vaginosismicrorounds. Accessed April 24, 2024.
22. Gardella C, Eckert LO, Lentz GM. Genital tract infections: vulva, vagina, cervix, toxic shock syndrome, endometritis, and salpingitis. In: Lobo RA, Gershenson DM, Lentz GM, Valea FA,eds.
Comprehensive Gynecology. 7th ed. Philadelphia, PA: Elsevier; 2016.
23. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines, 2015. MMWR Recomm Rep 2015; 64: 1-137.
24. Brown RG, Marchesi JR, Lee YS, et al. Vaginal dysbiosis increases risk of preterm fetal membrane rupture, neonatal sepsis and is exacerbated by erythromycin. BMC Med 2018; 16: 9.
25. Fredricks DN, Fiedler TL, Thomas KK, Oakley BB, Marrazzo JM. Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol 2007; 45: 3270–3276.
26. Brotman RM, Klebanoff MA, Tonia R et al. Bacterial Vaginosis Assessed by Gram Stain and Diminished Colonization Resistance to Incident Gonococcal, Chlamydial, and Trichomonal Genital
Infection. J Infect Dis 2010; 202: 1907-1915.
27. Haggerty CL, Totten PA, Tang G et al. Identification of novel microbes associated with pelvic inflammatory disease and infertility. Sex Transm Infect 2016; 92: 441-446.
28. Gaydos CA, Begaj S, Schwebke J et al. Clinical Validation of a Test for the Diagnosis of Vaginitis. Obstet Gynecol 2017; 130: 181-189.
29. Cohen CR, Wierzbicki MR, French AL, et al. Randomized trial of Lactin-V to prevent recurrence of bacterial vaginosis. N Engl J Med 2020; 382: 1906-1915.
30. Lev-Sagie A, Goldman-Wohl D, Cohen Y, et al. Vaginal microbiome transplantation in women with intractable bacterial vaginosis. Nat Med 2019; 25: 1500-1504.
31. Meites E, Llata E, Braxton J, et al. Trichomonas vaginalis in selected U.S. sexually transmitted disease clinics: testing, screening, and prevalence. Sex Transm Dis 2013; 40: 865–869.
32. Centers for Disease Control and Prevention. Trichomoniasis – CDC Basic Fact Sheet. https://www.cdc.gov/std/trichomonas/stdfact-trichomoniasis. Accessed April 24, 2024.
33. Schwebke JR, Bachmann LH. Trichomonas vaginalis. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 9th edition.
Philadelphia, PA: Elsevier; 2020.
34. Wiringa AE, Ness RB, Darville T, Beigi RH, Haggerty CL. Trichomonas vaginalis, endometritis and sequela among women with clinically suspected pelvic inflammatory disease. Sex Transm
Infect 2020; 96: 436-438.
35. Schwebke JR, Hobbs MM, Taylor SN, et al. Molecular testing for Trichomonas vaginalis in women: results from a prospective U.S. clinical trial. J Clin Microbiol 2011; 49: 4106-4111.
36. Kissinger P, Muzny CA, Mena LA, et al. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial. Lancet Infect
Dis 2018; 18: 1251-1259.
37. Das S, Huengsberg M, Shahmanesh M. Treatment failure of vaginal trichomoniasis in clinical practice. Int J STD AIDS 2005; 16: 284-286.
38. Schwebke JR, Desmond RA. A randomized controlled trial of partner notification methods for prevention of trichomoniasis in women. Sex Transm Dis 2010; 37: 392-396.
39. Goncalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: epidemiology, microbiology, and risk factors. Crit Rev Microbiol 2016; 42: 905-927.
40. Landers DV, Wiesenfeld HC, Heine RP, Krohn MA, Hillier SL. Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol 2004; 190: 1004–1010.
41. Holzer I, Farr A, Hagmann M, Petricevic L. The colonization with Candida species is more harmful in the second trimester of pregnancy. Arch Gynecol Obstet 2017; 295: 891-895.
42. Rumyantseva TA, Bellen G, Savochkina YA, Guschin AE, Donders GG. Diagnosis of aerobic vaginitis by quantitative real-time PCR. Arch Gynecol Obstet 2016; 294: 109-114.
43. Shroff S. Infectious Vaginitis, Cervicitis, and Pelvic Inflammatory Disease. Med Clin North Am 2023; 107: 299-315.
44. Cooke G, Watson C, Smith J, Pirotta M, van Driel ML. Treatment for recurrent vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev 2022; 1: CD009151.
45. Nurbhai M, Grimshaw J, Watson M, Bond CM, Mollison JA, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis
(thrush). Cochrane Database Syst Rev 2007: (4): CD002845.
46. Sobel JD, Kapernick PS, Zervos M, et al. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001; 185: 363-369.
47. Rosa MI, Silva BR, Pires PS et al. Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2013; 167: 132-
136.
48. Mølgard-Nielsen D, Svanström H, Melbye M, Hviid A, Pasternak B. Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth. JAMA 2016;
315: 58-67.
SERVİSİT VE ENDOMETRİT
KAYNAKLAR
1. Abdallah M, Augenbraun MH, McCormak W. Vulvovaginitis and Cervicitis. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases.
9th edition. Philadelphia, PA: Elsevier; 2020.
2. Shroff S. Infectious Vaginitis, Cervicitis, and Pelvic Inflammatory Disease. Med Clin North Am 2023; 107: 299-315.
3. Ortiz-de la Tabla V, Gutiérrez F. Cervicitis: Etiology, diagnosis and treatment. Enferm Infecc Microbiol Clin (Engl Ed) 2019; 37: 661-667.
4. Marrazzo JM, Martin DH. Management of women with cervicitis. Clin Infect Dis 2007; 44: 102–110.
5. Manhart LE, Critchlow CW, Holmes KK, et al. Mucopurulent cervicitis and Mycoplasma genitalium. J Infect Dis 2003; 187: 650-657.
6. Curry A, Williams T, Penny ML. Pelvic inflammatory disease: Diagnosis, management, and prevention. Am Fam Physician 2019; 100: 357-364.
7. Lusk MJ, Konecny P. Cervicitis: a review. Curr Opin Infect Dis 2008; 21: 49–55.
8. Kletzel HH, Rotem R, Barg M, Michaeli J, Reichman O. Ureaplasma urealyticum:the role as a pathogen in women’s health, a systematic review. Curr Infect Dis Rep 2018; 29: 33.
9. McGowin CL, Radtke AL, Abraham K, Martin DH, Herbst-Kralovetz M. Mycoplasma genitalium infection activates cellular host defense and inflamma-tion pathways in a 3-dimensional
human endocervical epithelial cell model. J Infect Dis 2013; 207: 1857–1868.
10. Rours GI, Duijts L, Moll HA, et al. Chlamydia trachomatis infection during pregnancy associated with preterm delivery: apopulation-based prospective cohort study. Eur J Epidemiol 2011;
26: 493–502.
11. Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infectionand female reproductive tract disease: a meta-analysis. Clin Infect Dis 2015; 61: 418–26.
12. Lusk MJ, Garden FL, Rawlinson WD, Naing ZW, Cumming RG, Konecny P. Cervicitis etiology and case definition: a study in Australian women attending sexuallytransmitted infection
clinics. Sex Transm Infect 2016; 92: 175–181.
13. Workowski KA, Bolan GA. Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep 2015; 64: 1–137.
14. Singh N, Sethi A. Endometritis – Diagnosis,Treatment and its impact on fertility – A Scoping Review. JBRA Assist Reprod 2022; 26: 538-546.
15. Kitaya K, Takeuchi T, Mizuta S, Matsubayashi H, Ishikawa T. Endometritis: new time, new concepts. Fertil Steril 2018; 110: 344-350.
16. Kushnir VA, Solouki S, Sarig-Meth T, et al. Systemic Inflammation and Autoimmunity in Women with Chronic Endometritis. Am J Reprod Immunol 2016; 75: 672-677.
17. McQueen DB, Bernardi LA, Stephenson MD. Chronic endometritis in women with recurrent early pregnancy loss and/or fetal demise. Fertil Steril 2014; 101: 1026-1030.
18. Cicinelli E, Matteo M, Tinelli R, et al. Prevalence of chronic endometritis in repeated unexplained implantation failure and the IVF success rate after antibiotic therapy. Hum Reprod 2015; 30:
323–330.
19. McQueen DB, Perfetto CO, Hazard FK, Lathi RB. Pregnancy outcomes in women with chronic endometritis and recurrent pregnancy loss. Fertil Steril 2015; 104: 927–931.
20. Kitaya K, Matsubayashi H, Takaya Y, et al. Live birth rate following oral antibiotic treatment for chronic endometritis in infertile women with repeated implantation failure. Am J Reprod
Immunol 2017; 78: e12719.
21. Khan KN, Fujishita A, KitajimaM, Hiraki K, Nakashima M, Masuzaki H. Intrauterine microbial colonization and occurrence of endometritis in women with endometriosis. Hum Reprod
2014; 29: 2446–2456.
22. Pitsos M, Skurnick J, Heller D. Association of pathologic diagnoses with clinical findings in chronic endometritis. J Reprod Med 2009; 54: 373–377.
23. Kitaya K, Yamaguchi T, Yasuo T, Okubo T, Honjo H. Post-ovulatory rise of endometrial CD16 (–) natural killer cells: in situ proliferation of residual cells or selective recruitment from circu-
lating peripheral blood? J Reprod Immunol 2007; 76: 45–53.
24. Akopians AL, Pisarska MD, Wang ET. The role of inflammatory pathways in implantation failure: chronic endometritis and hydrosalpinges. Semin Reprod Med 2015; 33: 298–304.
25. Kitaya K, Matsubayashi H, Yamaguchi K, et al. Chronic endometritis: potential cause of infertility and obstetric and neonatal complications. Am J Reprod Immunol 2016; 75: 13–22.
26. Moreno I, Cicinelli E, Garcia-Grau I, et al. The diagnosis of chronic endometritis in infertile asymptomatic women: a comparative study of histology, microbial cultures, hysteroscopy, and
molecular microbiology. Am J Obstet Gynecol 2018; 218: 602.e1-e16.
27. Shah HU, Sannananja B, Baheti AD, Udare AS, Badhe PV. Hysterosalpingography and ultrasonogra-phy findings of female genital tuberculosis. Diagn Interv Radiol 2015; 21: 10-15.
28. Sharma JB, Karmakar D, Kumar R, et al. Comparison of PET/CT with other imaging modalities in women with genital tuberculosis. Int J Gynaecol Obstet 2012; 118: 123-128.
PELVİK ENFLAMATUVAR HASTALIK VE TUBO-OVARYAN APSE
KAYNAKLAR
1. Yusuf H, Trent M. Management of Pelvic Inflammatory Disease in Clinical Practice. Ther Clin Risk Manag 2023; 19: 183-192.
2. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70: 1-187.
3. Curry A, Williams T, Penny ML. Pelvic Inflammatory Disease: Diagnosis, Management, and Prevention. Am Fam Physician 2019; 100: 357-364.
4. Darville T, Pelvic Inflammatory Disease Workshop Proceedings Committee. Pelvic inflammatory disease: identifying research gaps—proceedings of a workshop sponsored by Department of
Health and Human Services/National Institutes of Health/National Institute of Allergy and Infectious Diseases, November 3–4, 2011. Sex Transm Dis 2013; 40: 761–767.
5. Wiesenfeld HC, Hillier SL, Meyn LA, Amortegui AJ, Sweet RL. Subclinical pelvic inflammatory disease and infertility. Obstet Gynecol 2012; 120: 37–43.
6. Soper DE. Pelvic inflammatory disease. Obstet Gynecol 2010; 116: 419-428.
7. Kreisel K, Torrone E, Bernstein K, Hong J, Gorwitz R. Prevalence of pelvic inflammatory disease in sexually experienced women of reproductive age — United States, 2013–2014.
MMWR Morb Mortal Wkly Rep 2017; 66: 80–83.
8. Simms I, Stephenson JM, Mallinson H, et al. Risk factors associated with pelvic inflammatory disease. Sex Transm Infect 2006; 82: 452-457.
9. Price MJ, Ades AE, Welton NJ, Simms I, Macleod J, Horner PJ. Proportion of pelvic inflammatory disease cases caused by chlamydia trachomatis: consistent picture from different methods.
J Infect Dis 2016; 214: 617–624.
10. Price MJ, Ades AE, De Angelis D, et al. Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model. Am J Epidemiol
2013; 178: 484-492.
11. Burnett AM, Anderson CP, Zwank MD. Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis.Am J Emerg Med 2012;
30: 1114–1117.
12. Wiesenfeld HC, Meyn LA, Darville T, Macio IS, Hillier SL. A randomized controlled trial of ceftriaxone and doxycycline, with or without metronidazole, for the treatment of acute pelvic
inflammatory disease. Clin Infect Dis 2021; 72: 1181–1189.
13. Haggerty CL, Totten PA, Tang G, et al. Identification of novel microbes associated with pelvic inflammatory disease and infertility. Sex Transm Infect 2016; 92: 441-446.
14. Mitchell C, Prabhu M. Pelvic inflammatory disease: current concepts in pathogenesis, diagnosis and treatment. Infect Dis Clin North Am 2013; 27: 4.
15. Trent M. Pelvic inflammatory disease. Pediatr Rev 2013; 34: 163–172.
16. Brunham RC, Gottlieb SL, Paavonen J. Pelvic inflammatory disease. N Engl J Med 2015; 372: 2039-2048.
17. Haggerty CL, Gottlieb SL, Taylor BD, Xu NLF, Ness RB. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis 2010; 201: 134-155.
18. Chen PC, Li PC, Ding DC. Pelvic inflammatory disease and causative pathogens in older women in a medical center in eastern Taiwan: a retrospective cross-sectional study. PLoS One 2021;
16: e0257627.
19. Anyalechi GE, Hong J, Kreisel K, et al. Self-reported infertility and associated pelvic inflammatory disease among women of reproductive age — national health and nutrition examination
survey, United States, 2013–2016. Sex Transm Dis 2019; 46: 446–451.
20. Lunny C, Taylor D, Hoang L, et al. Self-collected versus cliniciancollected sampling for chlamydia and gonorrhea screening: a systemic review and meta-analysis. PLoS One 2015; 10: e0132776.
21. Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep 2017; 6: 34-41.
22. Kitaya K, Takeuchi T, Mizuta S, Matsubayashi H, Ishikawa T. Endometritis: new time, new concepts. Fertil Steril 2018; 110: 344-350.
23. Sakhel K, Benson CB, Platt LD, Goldstein R, Benacerraf BR. Begin with the basics: role of 3-dimensional sonography as a first-line imaging technique in the costeffective evaluation of gyne-
cologic pelvic disease. J Ultrasound Med 2013; 32: 381-388.
24. Molander P, Sjöberg J, Paavonen J, Cacciatore JP. Transvaginal power Doppler findings in laparoscopically proven acute pelvic inflammatory disease. Ultrasound Obstet Gynecol 2001; 17:
233-238.
25. Revzin MV, Mathur M, Dave HB, Macer ML, Spektor M. Pelvic inflammatory disease: multimodality imaging approach with clinical-pathologic correlation. Radiographics 2016; 36: 1579-
1596.
26. Sweet RL. Treatment of acute pelvic inflammatory disease. Infect Dis Obstet Gynecol 2011; 2011: 561909.
27. Petrina MAB, Cosentino LA, Wiesenfeld HC, DarvilleT, Hillier SL. Susceptibility of endometrial isolates recovered from women with clinical pelvic inflammatory disease or histological
endometritis to antimicrobial agents. Anaerobe 2019; 56: 61-65.
28. Haggerty CL, Ness RB, Amortegui A, et al. Endometritis does not predict reproductive morbidity after pelvic inflammatory disease. Am J Obstet Gynecol 2003; 188: 141–148.
29. Boothby M, Page J, Pryor R, Ross JD. A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for firstline treatment of uncomplicated non-gonococcal pelvic
inflammatory disease. Int J STD AIDS 2010; 21: 195–197.
30. Judlin P, Liao Q, Liu Z, Reimnitz P, Hampel B, Arvis P. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG 2010; 117: 1475–1484.
31. Fung M, Scott KC, KentCK, KlausnerJD. Chlamydial and gonococcal reinfection among men: a systematic review of data to evaluate the need for retesting. Sex Transm Infect 2007; 83:
304–309.
32. Jatlaoui TC, Riley HEM, Curtis KM. The safety of intrauterine devices among young women: a systematic review. Contraception 2017; 95: 17–39.
33. Chen MJ, Kim CR, Whitehouse KC, Berry-Bibee E, Gaffield ME. Development, updates, and future directions of the World Health Organization Selected Practice Recommendations for
Contraceptive Use. Int J Gynaecol Obstet 2017; 136: 113–119.
34. Tepper NK, Steenland MW, Gaffield ME, Marchbanks PA, Curtis KM. Retention of intrauterine devices in women who acquire pelvic inflammatory disease: a systematic review. Contracep-
tion 2013; 87: 655–660.
35. Kairys N, Roepke C. Tubo-Ovarian Abscess. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 2023 Jun 12.
36. Tao X, Ge SQ, Chen L, Cai LS, Hwang MF, Wang CL. Relationships between female infertility and female genital infections and pelvic inflammatory disease: a population-based nested cont-
rolled study. Clinics (Sao Paulo) 2018; 73: e364.
37. Fouks Y, Cohen A, Shapira U, Solomon N, Almog B, Levin I. Surgical Intervention in Patients with Tubo-Ovarian Abscess: Clinical Predictors and a Simple Risk Score. J Minim Invasive
Gynecol 2019; 26: 535-543.
38. Fouks Y, Cohen Y, Tulandi T, Meiri A, Levin I, Almog B, Cohen A. Complicated Clinical Course and Poor Reproductive Outcomes of Women with Tubo-Ovarian Abscess after Fertility
Treatments. J Minim Invasive Gynecol 2019; 26: 162-168.
39. Bridwell RE, Koyfman A, Long B. High risk and low prevalence diseases: Tubo-ovarian abscess. Am J Emerg Med 2022; 57: 70-75.
40. Dessein R, Giraudet G, Marceau L, et al. Identification of sexually transmitted bacteria in tubo-ovarian abscesses through nucleic acid amplification. J Clin Microbiol 2015; 53: 357-359.
41. Sordia-Hernández LH, Serrano Castro LG, Sordia-Piñeyro MO, Morales Martinez A, Sepulveda Orozco MC, Guerrero-Gonzalez G. Comparative study of the clinical features of patients with
a tubo-ovarian abscess and patients with severe pelvic inflammatory disease. Int J Gynaecol Obstet 2016; 132: 17-19.
42. Chen KY, Tseng JY, Yang CY. Tubo-ovarian abscess with sepsis in a nonagenarian woman: a case report and literature review. BMC Womens Health 2019; 19: 81.
43. Munro K, Gharaibeh A, Nagabushanam S, Martin C. Diagnosis and management of tubo-ovarian abscesses. Obstet Gynaecol 2018; 20: 11–19.
44. Najib B, Abdallah W, Haddad E, Atallah D. Brucella pelvic tubo-ovarian abscess with a history of chronic brucellosis. IDCases 2020; 23: e01029.
45. Nernsai P, Sophonsritsuk A, Lertvikool S, Jinawath A, Chitasombat MN. A case report of Tubo-ovarian abscess caused by Burkholderia pseudomallei. BMC Infect Dis 2018; 18: 73.
46. Cho HW, Koo YJ, Min KJ, Hong JH, Lee JK. Pelvic Inflammatory Disease in Virgin Women With Tubo-ovarian Abscess: A Single-Center Experience and Literature Review. J Pediatr Adolesc
Gynecol 2017; 30: 203-208.
47. Demirtas O, Akman L, Demirtas GS, Hursitoglu BS, Yilmaz H. The role of the serum inflammatory markers for predicting the tubo-ovarian abscess in acute pelvic inflammatory disease: a
single-center 5-year experience. Arch Gynecol Obstet 2013; 287: 519–523.
48. Erenel H, Yilmaz N, Oncul M, et al. Usefulness of Serum Procalcitonin Levels in Predicting Tubo-Ovarian Abscess in Patients with Acute Pelvic Inflammatory Disease. Gynecol Obstet Invest
2017; 82: 262-266